Table 4.
Adjusted hazard ratios, 95% confidence intervals, and incidence rates of end-stage renal disease development according to the change of MetS component in different renal function groups.
| eGFR (ml/min 1.73 m2) | Met S | N | Events (n) | Follow-up duration (person-years) | Incidence rate (per 1000 person-years) | Adjusted hazard ratios ( 95% confidence intervals) | ||
|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||||
| ≥ 90 | ||||||||
| No (–/–) | 3,860,370 | 743 | 19,327,628 | 0.04 | 1 (ref.) | 1 (ref.) | 1 (ref.) | |
| Post (–/+) | 569,066 | 238 | 2,827,416 | 0.08 | 1.53 (1.32, 1.77) | 1.70 (1.46, 1.98) | 1.70 (1.46, 1.98) | |
| Pre (+/–) | 443,490 | 165 | 2,207,881 | 0.07 | 1.29 (1.09, 1.53) | 1.42 (1.19, 1.68) | 1.42 (1.19,1.68) | |
| Both (+/+) | 886,095 | 604 | 4,386,917 | 0.14 | 2.10 (1.88, 2.35) | 2.49 (2.20, 2.82) | 2.49 (2.20, 2.82) | |
| 60–90 | ||||||||
| No (–/–) | 4,033,388 | 1287 | 20,186,181 | 0.06 | 1 (ref.) | 1 (ref.) | 1 (ref.) | |
| Post (–/+) | 782,638 | 578 | 3,892,718 | 0.15 | 1.70 (1.54, 1.88) | 1.92 (1.73, 2.12) | 1.88 (1.70, 2.08) | |
| Pre (+/–) | 598,265 | 392 | 2,981,306 | 0.13 | 1.45 (1.29,1.62) | 1.61 (1.43, 1.80) | 1.59 (1.41, 1.78) | |
| Both (+/+) | 1,438,726 | 1935 | 7,125,683 | 0.27 | 2.66 (2.47, 2.86) | 3.21 (2.96, 3.48) | 3.12 (2.88, 3.39) | |
| < 60 | ||||||||
| No (–/–) | 273,575 | 1900 | 1,383,148 | 1.37 | 1 (ref.) | 1 (ref.) | 1 (ref.) | |
| Post (–/+) | 86,721 | 1394 | 427,189 | 3.26 | 2.30 (2.14, 2.46) | 2.85 (2.65, 3.06) | 3.32 (3.09,3.57) | |
| Pre (+/–) | 63,867 | 1011 | 3,134,865 | 3.23 | 2.29 (2.12, 2.47) | 2.75 (2.55, 2.98) | 3.12(2.89, 3.38) | |
| Both (+/+) | 274,723 | 8335 | 1,326,542 | 6.28 | 4.70 (4.45, 4.95) | 6.47 (6.11, 6.85) | 7.95 (7.50, 8.42) | |
Model 1, adjusted for No. of MetS components at 1st visit, age and sex; Model 2, Model 1 plus adjusted for smoking, drinking and exercise; Model 3, Model 2 plus adjusted for estimated GFR.